ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 186,07
-0,12%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioLineRx Ltd (BLRX)

  7. BioLineRx Ltd (BLRX) Actualités

BLRX

BioLineRx (BLRX)

BioLineRx Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BLRX
DateHeureSourceTitreSymboleSociété
24/05/202413h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
17/04/202413h00PR Newswire (US)BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingNASDAQ:BLRXBioLineRx Ltd
08/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BLRXBioLineRx Ltd
29/12/202322h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLRXBioLineRx Ltd
29/12/202322h15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BLRXBioLineRx Ltd
20/11/202312h25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:BLRXBioLineRx Ltd
01/11/202312h43PR Newswire (Canada)BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
31/10/202314h00PR Newswire (Canada)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
26/10/202320h18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BLRXBioLineRx Ltd
18/10/202323h07AllPennyStocks.comNew Collaboration Could Revolutionize Treatment of Chronic Spinal Cord InjuriesNASDAQ:BLRXBioLineRx Ltd
11/09/202313h00PR Newswire (US)BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaNASDAQ:BLRXBioLineRx Ltd
30/08/202313h16IH Market NewsWednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and moreNASDAQ:BLRXBioLineRx Ltd
23/06/202322h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
22/03/202312h48Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:BLRXBioLineRx Ltd
20/01/202322h32Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BLRXBioLineRx Ltd
15/11/202218h05TipRanksBioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. WainwrightNASDAQ:BLRXBioLineRx Ltd
04/11/202221h30PR Newswire (US)BioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:BLRXBioLineRx Ltd
28/09/202218h15TipRanksBioline RX Ltd Sponsored ADR (BLRX) Gets a Buy from H.C. WainwrightNASDAQ:BLRXBioLineRx Ltd
20/09/202222h31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BLRXBioLineRx Ltd
19/09/202216h53TipRanksBioLineRx (NASDAQ:BLRX) Nosedives on $15M Direct OfferingNASDAQ:BLRXBioLineRx Ltd
09/09/202222h16Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:BLRXBioLineRx Ltd
30/06/202215h42PR Newswire (Canada)BioLineRx conclut une entente de codéveloppement avec GenFleet pour développer davantage le Motixafortide pour le traitement de l'adénocarcinome canalaire pancréatique, selon les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
29/06/202214h00PR Newswire (Canada)BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
16/03/202216h15TipRanksH.C. Wainwright Thinks Biolinerx’s Stock is Going to RecoverNASDAQ:BLRXBioLineRx Ltd
11/02/202212h50Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BLRXBioLineRx Ltd
18/01/202217h40TipRanksBiolinerx (BLRX) Receives a Buy from H.C. WainwrightNASDAQ:BLRXBioLineRx Ltd
21/09/202118h13Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:BLRXBioLineRx Ltd
25/02/202112h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BLRXBioLineRx Ltd
23/02/202115h13Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:BLRXBioLineRx Ltd
28/01/202117h31TipRanksThese 2 Penny Stocks Could Rally All the Way to $11, Say AnalystsNASDAQ:BLRXBioLineRx Ltd
 Showing the most relevant articles for your search:NASDAQ:BLRX

Dernières Valeurs Consultées

BIT
P20SH8
NLBNPIT20SH8 20241220 28
USOTC
VMTHF
Venus Medtech Hangzhou (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés